New York, NY -- (SBWIRE) -- 07/07/2015 -- Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

Summary

Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.

Click on link to order this study: https://wiseguyreports.com/reports/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation

A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition implies that the approach to pancreatic cancer treatment is changing and first-in-class innovation is playing a significant role in this.

Scope

- Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement.

- What survival benefits do current therapies provide?

- What are the current unmet needs that the pipeline needs to address?

- The pipeline contains a plethora of molecule types and molecular targets not present on the market, including a large focus on therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.

- What impact will the emergence of biologics have on the pancreatic cancer landscape?

- Will pipeline diversity translate to clinically and commercially successful therapies?

- How will the rise of novel molecular target categories, such as signal transduction, impact future treatment options?

- 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.

- Do first-in-class products show strong progression into the later stages?

- Why is the greatest number of first-in-class products seen in signal transduction?

- Numerous early-stage, first-in-class products have high promise, often supported by preclinical evidence.

- How well are first-in-class targets, such as Akt2, aligned to known disease causing pathways?

- Does scientific literature provide significant rationale for therapies acting on early-stage promising, first-in-class targets?

- What does preclinical data on Akt inhibition suggest about its potential as a target in pancreatic cancer?

- Deals for first-in-class products typically take place in earlier stages than non-first-in-class counterparts, with 79% of first-in-class licensing deals occurring in Phase I or earlier.

- To what extent does first-in-class status influence deal value?

- Can biologics command a greater deal value than other molecule types?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.

- Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the pancreatic cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating pancreatic cancer.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential.Promising targets, including MAP3K7 and P70-S6 Kinase 1 have been extensively reviewed using peer-reviewed literature and preclinical data.

- Identify commercial opportunities in the pancreatic cancer deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of pancreatic cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Click on link to view Table of Content: https://wiseguyreports.com/reports/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation

https://wiseguyreports.com/reports/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation